LONDON (Reuters) - Roche of Switzerland has bought the rights to a second type of experimental Alzheimer's drug from privately-held AC Immune, raising its bet on finding a treatment for the degenerative brain disorder. The deal reflects continuing interest in Alzheimer's among big drugmakers, despite past setbacks and low expectations for two other drugs from rival companies that will report advanced-stage clinical trial results in a few months time. ...
Click here to read the rest
No comments:
Post a Comment